Faculty Profile

Jacobo Abadi, MD
Phone: 718-918-4461
E-mail: jacobo.abadi@nychhc.org

Dr. Abadi is an Attending in the Division of Pediatric Infectious Diseases. Dr. Abadi is a committee member of the New York State HIV Clinical Guidelines Program. Dr. Abadi is board-certified in Pediatric Infectious Diseases and he is an Associate Professor of Clinical Pediatrics at the Albert Einstein College of Medicine.

Medical School:

Luis Razetti School of Medicine, Central University Venezuela

Training:

  • Internship and Residency: Montefiore Medical Center
  • Infectious Disease Fellowship: Montefiore Medical Center

Bibliography:

  • Sharp ER, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, et al: Nixon DF. Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children. PLoS One 2012;7(1):e29154.
  • Sharp ER, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, et al: Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents. PLoS One 2011;6(7):e21135.
  • Phillips UK, Rosenberg MG, Dobroszycki Wiznia AA, Abadi J. et al: Pregnancy in women with perinatally acquired HIV-infection: outcomes and challenges. AIDS Care 2011 Sep;23(9):1076-82.
  • Ballan WM, Wiznia AA, Abadi J, Fennelly GJ, Rosenberg MG, et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007 Sep 1;179(5):3362-70.
  • Toussi SS, Abadi J, Rosenberg M, et al: Prevalence of hepatitis B and C virus infections in children infected with HIV. Clin Infect Dis 2007;45:795-8.
  • Rosenberg M, Abadi J, Dobroszycki J, Wiznia A. Progress and Challenges in Antiretroviral Therapy of HIV-infected Children. Current Infectious Disease Reports, 2006 8:324-33.
  • Ballan WM, Vu BA, Abadi J, et al: Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007;179:3362-70.
  • Abadi J, Sprecher E, Rosenberg MG, et al: Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr 2006r;41:298-303.

Publications

  • Dehority W, Abadi J, Wiznia A, Viani RM. Use of integrase inhibitors in hiv-infected children and adolescents. Drugs. 2015 Sep;75(13):1483-97.